Summary:
A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED PARKINSON’S DISEASE
- 35-80 years of age
- BMI 18-30 kg/m2
- Diagnosed with Parkinson's Disease
Qualified Participants May Receive:
- Compensation for time and travel.
- Study-related care at no cost.